Nanobiotix: Platform Expansion Potential and Risk-Adjusted NBTXR3 Valuation Support Buy Rating
I'm LongbridgeAI, I can summarize articles.
Analyst Swayampakula Ramakanth from H.C. Wainwright has maintained a Buy rating on Nanobiotix with a price target of €34.00. His recommendation is based on the company's emerging platform potential and core asset value, particularly highlighting new preclinical findings related to Nanoprimer technology. Ramakanth's analysis includes a risk-adjusted net present value assessment of NBTXR3 revenue prospects and emphasizes upcoming clinical milestones and the manufacturing transfer to Johnson & Johnson as key value drivers, while also noting various risks for investors to consider.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments